kytx: the income statement

MyFinsight

Kyverna Therapeutics, Inc. (KYTX)

For the quarter ending 2025-06-30, KYTX made $2,364K in revenue. -$42,100K in net income. Net profit margin of -1780.88%.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

	2025-06-30
Unrealized loss on available-for-sale marketable securities, net	-19
Total other comprehensive loss	-19
Research and development	35,816
General and administrative	8,594
Total operating expenses	44,410
Loss from operations	-44,410
Other expenses, net	-21
Interest income	2,364
Interest expense	14
Total other income, net	2,329
Net loss	-42,081
Net loss and other comprehensive loss	-42,100

Earnings per share, basic, total	-0.97
Earnings per share, diluted, total	-0.97
Weighted average number of shares outstanding, basic, total	43,225,365
Weighted average number of shares outstanding, diluted, total	43,225,365

Unit: Thousand (K) dollars (except for numbers of shares and EPS)